Internet-based Exposure Therapy for Panic Disorder

Sponsor
Karolinska Institutet (Other)
Overall Status
Completed
CT.gov ID
NCT03061448
Collaborator
(none)
61
1
2
3.9
15.5

Study Details

Study Description

Brief Summary

The purpose of this study is examine if an internet-based exposure therapy based on inhibitory learning is feasible, acceptable and effective in reducing panic symptoms amongst patients who suffer from panic disorder and agoraphobia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Internet-based cognitive-behavior therapy
N/A

Detailed Description

Trial objectives: Primary objective is to examine if an internet-based exposure therapy based on inhibitory learning is effective in reducing panic symptoms. The secondary objective is to study if the protocol is feasible and acceptable. Secondary objective is measured is examined on 1) number of participants completing the study protocol, 2) participants' satisfaction with the treatment, 3) therapists' ratings of acceptability. The aim of this study is to assess the feasibility, and pilot the design and delivery of a RCT that will subsequently form the framework for a larger RCT to evaluate the effectiveness of an exposure protocol based on inhibitory learning.

Trial Design: Randomized controlled pilot study with two groups randomly assigned to either Internet-based exposure therapy based on the principles of inhibitory learning or Internet-based exposure therapy based on the principles of habituation Duration: Eight weeks

Primary Endpoint: Change in panic symptoms from baseline to Week 8. Efficacy Parameters:

Panic Disorder Severity Scale - Self rated (PDSS-SR) Safety Parameters: Adverse Events is assessed weekly via the internet. Description of Trial Subjects: Patients > 18 years old with a PDSS-SR score more than 6 points Number of Subjects: 80

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Internet-based Exposure Therapy for Panic Disorder: A Randomized Controlled Pilot Study
Actual Study Start Date :
Feb 1, 2017
Actual Primary Completion Date :
Jun 1, 2017
Actual Study Completion Date :
Jun 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Inhibitory learning based treatment

The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.

Behavioral: Internet-based cognitive-behavior therapy
Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.

Active Comparator: Habituation based treatment

The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).

Behavioral: Internet-based cognitive-behavior therapy
Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.

Outcome Measures

Primary Outcome Measures

  1. Panic Disorder Severity Scale - Self rated (PDSS-SR) [Week 0, Week 8]

    Change in panic symptoms from baseline to Week 8

Secondary Outcome Measures

  1. Credibility/Expectancy Questionnaire (CEQ) [Week 2]

    Measuring treatment expectancy and rationale credibility for use in clinical outcome studies

  2. Client Satisfaction Questionnaire (CSQ) [Week 8]

    To assess client satisfaction with treatment

  3. Adverse events scale [Week 8]

    To assess any adverse events caused by the treatment

  4. Patient Health Questionnaire (PHQ-9) [Week 0, Week 8]

    Change in depression from baseline to Week 8

  5. Anxiety Sensitivity Index (ASI) [Week 0, Week 8]

    Change in fear of anxiety-related physical sensations

  6. Agoraphobic Cognitions Questionnaire (ACQ) [Week 0, Week 8]

    Change in fear of fear in agoraphobics

  7. Body Sensations Questionnaire (BSQ) [Week 0, Week 8]

    Change in fear of bodily sensations in agoraphobics

  8. Brunnsviken Quality of Life Questionnaire (BBQ) [Week 0, Week 8]

    Change in self-perceived quality of life from baseline to week 8

  9. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) [Week 0, Week 8]

    Change in functioning and disability

  10. Generalised Anxiety Disorder Assessment (GAD-7) [Week 0, Week 8]

    Screening tool and severity measure for generalised anxiety disorder

  11. The Cardiac Anxiety Questionnaire (CAQ) [Week 0, Week 8]

    Change in heart-focused anxiety from baseline to week 8

  12. HA-NI-SSD Symptom Preoccupation Scale - testversion (SPSt) [Week 0, Week 8]

    Change in preoccupation of symptoms from baseline to week 8

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Outpatients

  • ≥ 18 years

  • Situated in Sweden

  • Informed consent

  • Panic Disorder Severity Scale - self rated score more than 6 points

Exclusion Criteria:
  • Substance dependence during the last six months

  • Post traumatic stress disorder, bipolar disorder or psychosis

  • Symptoms better explained by axis 2 diagnosis (e.g. autism or borderline personality disorder)

  • MADRS-S score above 25 points

  • Psychotropic medication changes within one months prior to treatment that could affect target symptoms.

  • Received exposure based Cognitive behavior therapy (CBT) for pathological worry the last 2 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska Institutet Stockholm Sweden 17177

Sponsors and Collaborators

  • Karolinska Institutet

Investigators

  • Principal Investigator: Erik M Andersson, PhD, Karolinska Institutet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Erik Andersson, PhD, psychologist, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT03061448
Other Study ID Numbers:
  • 2016/2422-31
First Posted:
Feb 23, 2017
Last Update Posted:
Aug 22, 2017
Last Verified:
Aug 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2017